- Home
- COYA
COYA
Coya Therapeutics Inc.
as 11-15-2024 4:00pm EST
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | N/A | IPO Year: | 2022 |
| Target Price: | $16.67 | AVG Volume (30 days): | 156.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.75 - $10.69 | Next Earning Date: | 11-06-2024 |
| Revenue: | $9,554,315 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -16.51% | Revenue Growth (next year): | 54.20% |
Stock Insider Trading Activity of Coya Therapeutics Inc. (COYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swaminathan Arun | COYA | Chief Executive Officer | Nov 13 '24 | Buy | $7.36 | 5,000 | $36,797.00 | 10,000 | |
| Swaminathan Arun | COYA | Chief Executive Officer | Nov 11 '24 | Buy | $7.34 | 5,000 | $36,689.00 | 10,000 |
Latest Coya Therapeutics Inc. News
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
Business Wire
11 days ago
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
MT Newswires
16 days ago
Coya Therapeutics New CEO Arun Swaminathan Takes Helm
Business Wire
16 days ago
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
TipRanks
18 days ago
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
MT Newswires
19 days ago
Sector Update: Health Care Stocks Ease Late Afternoon
Benzinga
19 days ago
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
MT Newswires
19 days ago
Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results
Business Wire
20 days ago
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
Compare COYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.